Reduced miR-215 expression predicts poor prognosis in patients with acute myeloid leukemia

• Published in: Japanese journal of clinical oncology Vol. 46; no. 4; pp. 350 - 356
• Main Authors: Wang, Yu-Xin, Zhang, Ting-Juan, Yang, Dong-Qin, Yao, Dong-Ming, Yang, Lei, Zhou, Jing-Dong, Deng, Zhao-Qun, Ma, Ji-Chun, Guo, Hong, Wen, Xiang-Mei, Lin, Jiang, Qian, Jun
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.04.2016
• Subjects: Aged; Down-Regulation; Female; fms-Like Tyrosine Kinase 3 - genetics; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute - metabolism; Leukemia, Myeloid, Acute - mortality; Leukemia, Myeloid, Acute - pathology; Male; MicroRNAs - metabolism; Middle Aged; Mutation; Original; Predictive Value of Tests; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; ROC Curve; MiR-215; acute myeloid leukemia; prognosis; real-time quantitative PCR
• ISSN: 0368-2811; 1465-3621
• DOI: 10.1093/jjco/hyv204

Abnormal expression of microRNA-215 has been identified in a variety of solid cancers. However, little is known about the expression pattern of microRNA-215 in acute myeloid leukemia. This study was to investigate the status of microRNA-215 expression and further analyze its clinical significance in acute myeloid leukemia. Real-time quantitative polymerase chain reaction assay was performed to evaluate the expression level of microRNA-215 in 113 patients with acute myeloid leukemia. Besides, the relationship between microRNA-215 levels and clinical and pathological factors was explored. Compared with the healthy individuals, microRNA-215 expression in acute myeloid leukemia patients was significantly down-regulated (P= 0.001). MicroRNA-215 low-expressed patients had higher white blood cells than microRNA-215 high-expressed patients (P= 0.014). The incidence of FLT3/ITD mutation in the patients with low microRNA-215 expression was significantly higher than those with high microRNA-215 expression (P= 0.025). MicroRNA-215 low-expressed patients had significantly shorter overall survival than microRNA-215 high-expressed patients in both non-M3 acute myeloid leukemia patients and cytogenetically normal patients (P= 0.017 and P= 0.044, respectively). Meanwhile, multivariate analysis confirmed the adverse prognostic value of microRNA-215 expression in acute myeloid leukemia patients with non-M3 subtypes. Our study demonstrates that reduced microRNA-215 expression is a common event and is associated with poor clinical outcome in acute myeloid leukemia.